Colorectal cancer in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 20, Issue 1, 2004, Pages 43-48

  Krok, Karen L ^a   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Colon cancer; Colorectal carcinoma; Crohn disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR MARKER; URSODEOXYCHOLIC ACID;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DNA FINGERPRINTING; DYSPLASIA; ENDOSCOPY; ENTERITIS; HIGH RISK PATIENT; HUMAN; NONHUMAN; REVIEW; RISK REDUCTION; ULCERATIVE COLITIS;

EID: 4344592401     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200401000-00009     Document Type: Review

References (59)

1. Eaden JA, Abrams KR, Mayberry JF: The true risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gastroenterology 2001, 48:526-535.
2. Gillen CD, Walmsley RS, Prior P, et al.: Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994, 35:1590-1592.
3. Gyde SN, Prior P, Macartney JC, et al.: Malignancy in Crohn's disease. Gut 1980, 21:1024-1029.
4. Weedon DD, Shorter RG, Ilstrup DM, et al.: Crohn's disease and cancer. N Engl J Med 1973, 289:1099-1103.
5. Persson PG, Karlen P, Bernell O, et al.: Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675-1679.
6. Ekbom A, Helmick C, Zack M, et al.: Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990, 336:357-359.
7. Sharan R, Schoen RE: Cancer in inflammatory bowel disease: an evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 2002, 31:237-254.
8. Podolsky DK: Inflammatory bowel disease (2). N Engl J Med 1991, 325:1008-1016.
9. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865.
10. Wellenbucher RF, Austt DE, Chang CG, et al.: Genomic instability is an early event during the progression pathway of ulcerative colitis-related neoplasia. Am J Pathol 1999, 154:1825-1830.
11. Suzuki H, Harpaz N, Tarmin L, et al.: Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Res 1994, 54:4841-4844.
12. Tarmin L, Yin J, Harpaz N, et al.: Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995, 55:2035-2038.
13. Yin J, Harpaz N, Tong Y, et al.: p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993, 104:1633-1639.
14. Brentall TA, Crispen DA, Rabinovitch PS, et al.: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107:369-378.
15. Burmer GC, Crispin DA, Kolli VR, et al.: Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991, 3:167-172.
16. Ezaki T, Watanabe M, Inoue N, et al.: A specific genetic alteration on chromosome 6 in ulcerative colitis-associated colorectal cancers. Cancer Res 2003, 63:3747-3749. This article provides evidence that there may be novel tumor suppressor genes on chromosome 6 related to the carcinogenesis of ulcerative colitis but not to sporadic colorectal cancers.
17. Mikami T, Yoshida T, Akino F, et al.: Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonic tumors. Am J Clin Pathol 2003, 119:723-730. This article examines cell proliferation and apoptosis in both ulcerative colitis and sporadic colorectal cancers. It provides further evidence that there are definite variations between the two forms of colorectal cancer.
18. Sato F, Shibata D, Harpaz N, et al.: Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 2002, 62:6820-6822. This study demonstrates that HPP1 is a common early event in ulcerative colitis-associated carcinogenesis and may potentially be used clinically as a biomarker for early detection of colorectal cancer.
19. Azarschab P, Porschen R, Gregor M, et al.: Epigenetic control of the E-Cadherin gene (CDHI) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer 2002, 35:121-126. This study offers evidence for the methylation of CDH1 promoter as a potential biomarker for detecting ulcerative colitis patients at a higher risk for developing colorectal cancer.
20. Lashner BA, Bauer WM, Rybicki LA, et al.: Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am J Gastroenterol 2003, 98:1423-1427. This study provides statistically significant evidence that abnormal p53 immunohistochemistry is associated with a poor prognosis in patients with ulcerative colitis-associated colorectal cancer. This is another potential biomarker.
21. Karlen P, Lofberg R, Brostrom O, et al.: Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999, 94:1047-1052.
22. Ekbom A, Helmick C, Zack M, et al.: Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990, 323:1228-1233.
23. Askling J, Dickman PW, Karlen P, et al.: Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001, 120:1356-1362.
24. Soetikno RM, Lin OS, Heidenreich PA, et al.: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54. An interesting meta-analysis of 11 studies that shows a significantly higher risk for colorectal cancer in patients with PSC and ulcerative colitis than with ulcerative colitis alone. It offers suggestions for the best way to follow this patient population.
25. Stiehl A, Rudolph G, Sauer P, et al.: Biliary secretion of bile acids and lipids in primary sclerosing cholangitis: influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995, 23:283-289.
26. Fausa O, Schrumpf E, Elgjo K: Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991, 11:31-39.
27. Narumi S, Roberts JP, Edmond JC, et al.: Liver transplantation for sclerosing cholangitis. Hepatology 1995, 22:451-457.
28. Fraser AG, Orchard TR, Robinson EM, et al.: Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002, 16:1225-1232.
29. Itzkowitz S: Colon carcinogenesis in inflammatory bowel disease. J Clin Gastroenterol 2003, 36(suppl 5):S70-S74.
30. Ransohoff DF, Ridell RH, Levin B: Ulcerative colitis and colonic cancer: problems in assessing diagnostic usefulness of mucosal dysplasias. Dis Colon Rectum 1985, 28:383-388.
31. Vieth M, Stolte M, Mueller E, et al.: Bioptical differential diagnosis of adenomas, dysplasias and carcinomas in patients with ulcerative colitis. Leber Magen Darm 2000, 3:125-132.
32. Kudo S, Tamura S, Nakajima T, et al.: Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996, 44:8-14.
33. Rembacken BJ, Fujii T, Cairns A, et al.: Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000, 8:1211-1214.
34. Kiesslich R, Fritsch J, Holtmann M, et al.: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003, 124:880-888. A well designed study that examines methylene blue chromoendoscopy to aid in the earlier diagnosis of colorectal cancer.
35. Rabinovitch PS, Dziadon S, Brentnall TA, et al.: Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 1999, 59:5148-5153.
36. Chen R, Rabinovitch PS, Crispin DA, et al.: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 2003, 162:665-672. There appears to be widespread genomic instability in ulcerative colitis patients with neoplasia. This may be another biomarker for patients who are at a higher risk for developing colorectal cancer.
37. Gullberg K, Stahlberg D, Liljeqvist L, et al.: Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997, 112:1487-1492.
38. Lofberg R, Liljeqvist L, Lindquist K, et al.: Dysplasia and DNA aneuploidy in a pelvic pouch: report of a case. Dis Colon Rectum 1991, 34:280-283.
39. Rodriguez-Sanjuan JC, Polavieja MG, Naranjo A, et al.: Adenocarcinoma in an ileal pouch for ulcerative colitis [letter]. Dis Colon Rectum 1995, 38:779-780.
40. Sequens R: Cancer in the anal canal (transitional zone) after restorative proctocolectomy with stapled ileal pouch-anal anastomosis. Int J Colorectal Dis 1997, 12:254-255.
41. Stern H, Walfisch S, Mullen B, et al.: Cancer in an ileoanal reservoirs: a new late complication? Gut 1990, 31:473-475.
42. Ziv Y, Fazio VW, Sirimarco MT, et al.: Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 1994, 37:1281-1285.
43. Coull DB, Lee FD, Henderson AP, et al.: Risk of dysplasia in the columnar cuff after stapled restorative proctocolectomy. Br J Surg 2003, 90:72-75. This study offers a potentially new set of guidelines for treating patients with ulcerative colitis status after proctocolectomy.
44. Sylvester PA, Walsh M, Myerscough N, et al.: Mucin gene expression in the ileoanal reservoir is altered and may be relevant to the risk of inflammation and dysplasia. Gut 2002, 51:386-391. This study offers evidence that mucin gene expression may be a potential biomarker in patients' status after proctocolectomy.
45. Eaden J, Abrams K, Ekbom A, et al.: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000, 14:145-153.
46. Pinczowski D, Ekbom A, Baron J, et al.: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107:117-120.
47. Bansal P, Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996, 91:44-48.
48. Butterworth C Jr, Hatch K, Soong SJ, et al.: Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 1992, 166:803-809.
49. Heimburger D, Alexander C, Birch R, et al.: Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. JAMA 1988, 259:1525-1530.
50. Fruedenheim J, Graham S, Marshall J, et al.: Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991, 20:368-374.
51. Giovannucci E, Stampfer MJ, Colditz GA, et al.: Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993, 85:875-884.
52. Lashner BA, Heidenrich PA, Su GL, et al.: Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 1989, 97:255-259.
53. Lashner BA, Provencher KS, Seidner DL, et al.: The effect of folic acid supplementation on the risk of cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29-32.
54. Narisawa T, Fukaura Y, Terada K, et al.: Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Can Res 1999, 18:259-266.
55. Narisawa T, Fukaura Y, Terada K, et al.: Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res 1998, 89:1009-1013.
56. Rigas B, Tsioulias GJ, Allan C, et al.: The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994, 83:319-323.
57. Ikegami T, Matsuzaki Y, Shoda J, et al.: The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998, 134:129-139.
58. Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
59. Pardi DS, Loftus EV Jr, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893. A well-designed study that shows ursodiol may significantly decrease the risk of developing colorectal cancer in patients with PSC and ulcerative colitis.